Connectome's core product repeatedly measures brain activity to build individualized baselines and detect subtle cognitive changes over time. The platform integrates neural data with lifestyle factors such as sleep and activity to provide contextual insights into why cognitive performance shifts. The company says its approach extends brain monitoring beyond one-time clinical tests into real-world, longitudinal tracking and targets applications including ADHD and dementia detection. Connectome builds on research from Imperial College London's LUCID study and was founded in 2024 by neuroscientists Lucas Scherdel and Dr Rufus Mitchell-Heggs. It is based in Zurich and London and plans to roll out its product with select partners while continuing R&D and expanding into broader health and diagnostic use cases. Financially, Connectome recently closed a $2 million pre-seed round that included over $115,000 in non-dilutive public funding.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2026